Adani Power Limited reported a 13.5% year-on-year decline in net profit for the quarter ended June 2025 (Q1 FY26), even as the company maintained steady operations and announced a 1:5 stock split to enhance liquidity and accessibility for investors.
Click Here to Explore Adani Power Share Price
Financial Highlights for Q1 FY26
- Net Profit: ₹3,385 crore, down 13.5% compared to ₹3,914 crore in Q1 FY25
- Board Announcement: Approved a stock split in the ratio of 1:5
- Each equity share of face value ₹10 will be subdivided into 5 shares of ₹2 face value
- The move is expected to increase liquidity and make the stock more affordable to retail investor
CEO Commentary
S B Khyalia, CEO of Adani Power, emphasized the company’s resilience and forward-looking strategy:
“Adani Power’s stable financial performance this quarter is a testament to its resilience and core strengths, even in the face of variability in power demand and unpredictable weather.”
He further highlighted the company’s growth initiatives:
- Swift project execution
- Strategic acquisitions to reach 30 GW power capacity by 2030
- Early procurement of critical power equipment like ultra-supercritical boilers, turbines, and generators
Operational Strategy
Adani Power is focusing on:
- Reinforcing its competitive edge by securing key infrastructure ahead of schedule
- Sustainability and operational excellence
- Supporting India’s long-term energy demands by expanding generation capabilities
Quick Analysis
While the profit declined 13.5%, Adani Power continues to emphasize capacity expansion and project execution.
- The stock split is a shareholder-friendly move aimed at improving stock liquidity and investor participation.
- The management’s focus remains on long-term goals, especially the ambitious 30 GW target by 2030.
The Q1 performance, paired with the stock split announcement, signals the company’s continued commitment to growth despite near-term financial softness.
Also Read: Sensex Drops 300 Points, Nifty Below 24,700 Amid Trump’s Tariffs, FII Selling and Pharma Drag
